gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ELUTHealthcareBiotechnology

Elutia Inc. Class A Common Stock (ELUT)

$0.7509−1.15%
Close Nov 5, 2026 · split-adjusted
Nov 4, 2026$0.76▼ 17.43% in range
Nov 4, 2025Low $0.51 · High $1.22Nov 4, 2026
What changed · written from our data
As of Nov 5, 2026

Elutia closed at $0.75 on Nov 5, down 1.15%, 38.5% below its 52-week closing high. Volume of 87.5K shares was 1.09× its 20-day average (close to normal).

Split-adjusted performance: -8.4% over one month, -24.8% over six months, -18.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.43M, down 11.6% from a year earlier, with a net margin of -315.0%.

Short interest was 15.3K shares at the Oct 15 settlement, up 63.8% from the prior report (0.0% of float, 1.0 days to cover).

Market cap$33.3M44.3M shares
Revenue · quarter$2.4M−11.6% YoY
Diluted EPS$-0.17—
P/E · TTM0.6×P/S 2.7×
Net margin-315.0%Gross 59.6%
Dividend yieldNone
52-week range0.51 – 1.22−38.5% from high
Volume87.5K1.09× 20-day avg
Volatility · 60d62.2%Annualised
Short % of float0.0%1.0 days to cover
Net cash$19.9MCash $19.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.7%1M −8.4%3M −11.7%6M −24.8%YTD +8.4%1Y −18.4%3Y −35.8%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum50
Revenue growth37
Net margin46
Value (low P/E)100
Size20

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short15.3K+63.8% vs prior
Days to cover1.0Settled Oct 15
% of float0.0%
Short vol. 10d35.9%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ELUTElutia$0.7509−1.15%−24.8%−11.6%−315.0%0.6$33.3M
INMBINmune Bio$1.18−11.65%−17.8%———$36.4MCompare
PTHSPelthos Therapeutics$9.30−8.37%−62.8%—−150.1%—$36.6MCompare
EXOZeXoZymes$4.11−4.64%−58.9%———$38.2MCompare
ALGSAligos Therapeutics$4.51−10.16%−25.2%+2778.5%−5.4%—$28.2MCompare
MGXMetagenomi Therapeutics$0.7308−7.49%−48.5%−103.0%——$27.6MCompare
LONALeonaBio$4.34−4.93%−56.0%———$40.9MCompare
CRBUCaribou Biosciences$0.4123−7.22%−78.1%−43.8%−1619.9%—$44.2MCompare
CVMCel-Sci$1.37−0.72%−14.4%———$24.1MCompare

News about Elutia

All news →
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Mar 13, 2026Neutral

Quick answers

What does Elutia do?
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients.
What is ELUT's market cap?
$33.26M, based on the Nov 5 close of $0.75.
What is ELUT's P/E ratio?
0.6× trailing-twelve-month earnings of $51.81M.
Does Elutia pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ELUT is sold short?
15.3K shares, 0.0% of float, as of Oct 15, 2026.
What sector is ELUT in?
Healthcare, in the Biotechnology industry.

About Elutia

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

HQ: Silver Spring, MD26 employeesListed Oct 8, 2020elutia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology